Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

C3N-00497

— · cohortSQ1

1f61f754-21a3-588a-8535-159344ac01b2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ1
subtype
cohortSQ1
age_years
64.99383984

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.540
  • INTERFERON_ALPHA_RESPONSE+0.450
  • E2F_TARGETS+0.430
  • INTERFERON_GAMMA_RESPONSE+0.420
  • MYC_TARGETS_V2+0.380
  • G2M_CHECKPOINT+0.370
  • IL6_JAK_STAT3_SIGNALING+0.360
  • MYC_TARGETS_V1+0.290
  • INFLAMMATORY_RESPONSE+0.140
  • OXIDATIVE_PHOSPHORYLATION+0.130

Top 10 suppressed

  • PROTEIN_SECRETION-0.440
  • HYPOXIA-0.370
  • COAGULATION-0.360
  • HEDGEHOG_SIGNALING-0.340
  • ESTROGEN_RESPONSE_EARLY-0.330
  • GLYCOLYSIS-0.330
  • MYOGENESIS-0.300
  • PEROXISOME-0.300
  • CHOLESTEROL_HOMEOSTASIS-0.290
  • FATTY_ACID_METABOLISM-0.290

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-90-A4EE-01A-11R-A24Z-07
lung-landscapes@6
—cohortSQ10.907
2TCGA-CR-6487-01A-11R-1873-07
head-neck@1
——0.878
3SRR8518253
breast-umap@18
—D0.856
4MBCProject_1542_T2_RNA
breast-umap@18
—D0.854
5SRR1313128
breast-umap@18
—D0.848
6SRR8518222
breast-umap@18
—D0.845
7SRR1313149
breast-umap@18
—D0.842
8TCGA-BH-A0B9-01A-11R-A056-07
breast-umap@18
—E0.841
9SRR11296816
colon-landscapes@1
——0.837
10SRR6013594
lung-landscapes@6
—cohortMD20.833

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.540Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.450Inavolisib— uncovered
E2F_TARGETS0.430Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.420Idelalisib— uncovered
MYC_TARGETS_V20.380Idelalisib— uncovered
G2M_CHECKPOINT0.370Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.360Inavolisib— uncovered
MYC_TARGETS_V10.290Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.140Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.130Remibrutinib— uncovered
APICAL_SURFACE0.110Temsirolimus— uncovered
DNA_REPAIR0.100Idelalisib— uncovered
IL2_STAT5_SIGNALING0.070Idelalisib— uncovered
MITOTIC_SPINDLE0.070Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.070Idelalisib— uncovered
COMPLEMENT0.050Inavolisib— uncovered
SPERMATOGENESIS0.010Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.010Inavolisib— uncovered